HK Stock MarketDetailed Quotes


  • 29.600
  • -0.950-3.11%
Market Closed Jul 19 16:08 CST
25.79BMarket Cap32.74P/E (TTM)

About HUTCHMED Company

Hutchison Pharmaceutical is an innovative biomedical company in the commercialization stage, aiming to become a global leader in the discovery, development and commercialization of targeted therapies and immunotherapy treatments for cancer and immune diseases. We are one of the first innovative pharmaceutical R&D companies in China to focus on the global market. Over the past 20 years, we have built a fully integrated R&D innovation platform with world-class discovery and development capabilities. As of 2020, we currently have a research and development team composed of about 600 professionals and 10 clinical-stage innovative anti-cancer drugs that are undergoing clinical research worldwide. We have also established a deep and profitable commercial platform in the Chinese market to manufacture, market and distribute prescription drugs and consumer health products in China, as well as our two innovative oncology drugs that have already been marketed in China — iutac (fruquintinib capsules) and suteta (surufatinib capsules). We are also expanding our commercialization footprint further into the US and Europe. Hutchison Pharmaceutical is listed on the Nasdaq Global Select Market and the London Alternative Investment Market (NASDAQ/London Stock Exchange: HCM).

Company Profile

Company NameHutchmed (China) co.,Ltd.
Listing DateJun 30, 2021
Issue Price40.10
Shares Offered104.00M share(s)
FoundedDec 18, 2000
Registered AddressCayman Islands
Chairmanlede ai
Secretaryxide shi
Audit InstitutionPricewaterhouseCoopers
Company CategoryOther
Registered OfficeP.O. Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business48/F, Cheung Kong Group Centre, 2 Queen's Road Central, Hong Kong
Fiscal Year Ends12-31
MarketHong Kong motherboard
BusinessHUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Company Executives

  • Name
  • Position
  • Salary
  • weiguo su
  • CEOs,Executive Director,Chief Scientific Officer
  • 4.11M
  • zefeng zheng
  • Executive Director,chief financial officer
  • 1.55M
  • lede ai
  • presidencies,Non-executive directors,Nomination Committee Members
  • 71.00K
  • xide shi
  • Non-executive directors,Remuneration Committee Members,Authorized Representative,Company Secretary
  • 71.00K
  • ling yang
  • Non-executive directors
  • --
  • Paul Rutherford CARTER
  • Senior Independent Non-Executive Director,Remuneration Committee Chairman,Audit Committee Members
  • --
  • Graeme Allan JACK
  • Independent Non-Executive Director,Chairman of the Audit Committee,Nomination Committee Members,Remuneration Committee Members
  • --
  • siya yan
  • Independent Non-Executive Director
  • --
  • shujin mo
  • Independent Non-Executive Director,Chairman of the Nomination Committee,Audit Committee Members
  • 186.00K
  • Marek KANIA
  • Executive Vice President,Chief Medical Officer,Head of R&D
  • --
  • zhenping wu
  • senior vice president
  • --
  • langzhi su
  • Special Adviser to the Technical Committee
  • --
  • jianhong li
  • senior vice president
  • --
  • qingmei wang
  • senior vice president
  • --
  • shixin li
  • Group Legal Director
  • --
  • kailun an
  • Executive Vice President,Chief Operating Officer
  • --
  • hong chen
  • senior vice president
  • --


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price